Publication | Open Access
Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model
24
Citations
39
References
2020
Year
Current Oncolytic VirotherapiesImmunologyImmunotherapyTumor BiologyCancer-associated VirusTranslational MedicineTumor ImmunityVaccine TrialLaboratory MedicineVc2 Promotes Long-lastingHemodialysisLimited Response RatesCell BiologyTumor MicroenvironmentCancer ImmunosurveillanceTherapeutic EfficacyImmune Checkpoint InhibitorVaccine EfficacyMedicineViral Oncology
Current oncolytic virotherapies possess limited response rates. However, when certain patient selection criteria are used, oncolytic virotherapy response rates have been shown to increase.
| Year | Citations | |
|---|---|---|
Page 1
Page 1